BUENA, N.J., Oct. 5, 2015 /PRNewswire/ -- IGI Laboratories,
Inc. (NYSE MKT: IG), a New
Jersey-based specialty generic pharmaceutical company, today
announced that Stephen Richardson
has been appointed Chief Scientific Officer (CSO) of IGI
Laboratories, Inc. effective October 5,
2015.
Jason Grenfell-Gardner, President
and CEO of IGI, commented, "We are excited to have Steve join the
IGI team. He brings over 30 years of R&D and regulatory
experience in the specialty pharmaceutical industry, in both the
topical and injectable markets. As CSO, Steve will lead our
R&D organization, including product development, analytical
methods and regulatory teams. For the past several months as a
Principal Consultant at Lachman Consulting Services, Inc., he has
been advising our team on how to best prepare for the new
environment under the Generic Drug Fee User Act, or GDUFA. As
a result, I am confident that Steve's transition into our
organization will be seamless. He is committed to our TICO
strategy and has a very successful track record of leading similar
products from the lab to regulatory approval."
Steve brings almost 30 years, of experience in the
specialty pharmaceutical industry, with a particular focus on
generics. Most recently, Steve was a Principal Consultant for
Lachman Consultant Services, Inc., where he provided expert
compliance, regulatory affairs and technical services to many
leading pharmaceutical and financial clients around the
world. Prior to Lachman, Steve served in various senior
leadership roles, most recently as the VP of Scientific and
Regulatory Affairs at JHP Pharmaceuticals, LLC, which was acquired
by Par Pharmaceuticals, Inc. in 2014. Steve was at JHP since
2007, and was an integral founding member of the Executive
Management team, where he had direct responsibility of a team of
thirty-five employees in both Regulatory and Medical Affairs, as
well as Product Development.
Prior to 2007, Steve gained a number of years of pharmaceutical
experience at Stiefel Laboratories, Mayne Pharma (USA), Inc., and Faulding Pharmaceuticals in
Australia. Steve has an MBA from the University of
Adelaide in Australia, and a BS in Chemistry/Microbiology
from the University of South
Australia.
Steve will report to Jason
Grenfell-Gardner and is a member of the Company's Executive
Management Team.
About IGI Laboratories, Inc.
IGI Laboratories is a
specialty generic pharmaceutical company. Our mission is to be
a leading player in the specialty generic prescription drug
market.
Forward-Looking Statements
This press release includes certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include, but are not
limited to, plans, objectives, expectations and intentions, and
other statements contained in this press release that are not
historical facts and statements identified by words such as "plan,"
"believe," "continue," "should" or words of similar meaning.
Factors that could cause actual results to differ materially from
these expectations include, but are not limited to: our inability
to meet current or future regulatory requirements in connection
with existing or future ANDAs; our inability to achieve
profitability; our failure to obtain FDA approvals as anticipated;
our inability to execute and implement our business plan and
strategy; the potential lack of market acceptance of our products;
our inability to protect our intellectual property rights; changes
in global political, economic, business, competitive, market and
regulatory factors; and our inability to complete successfully
future product acquisitions. These statements are based on
our current beliefs or expectations and are inherently subject to
various risks and uncertainties, including those set forth under
the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and other periodic reports we file with the Securities and Exchange
Commission. IGI Laboratories, Inc. does not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130827/MM70487LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/stephen-richardson-appointed-as-chief-scientific-officer-of-igi-laboratories-inc-300153604.html
SOURCE IGI Laboratories, Inc.